Role of Molecular Agents and Targeted Therapy in Clinical Trials for Women With Ovarian Cancer

International Journal of Gynecological Cancer - Tập 21 Số 4 - Trang 763-770 - 2011
Jonathan A. Ledermann1, Christian Marth2, Mark S. Carey3, Michael J. Birrer4, David D.L. Bowtell5, Stan B. Kaye6, Iain A. McNeish7, Amit M. Oza3, Giovanni Scambia8, Gordon Rustin7, Frederick B. Stehman4, David M. Gershenson9, Gillian Thomas9, Els M.J.J. Berns2,3, Antonio Casado2,3, Nelleke Ottevanger2,3, Felix Hilpert10, Byoung‐Gie Kim11, Aikou Okamoto12, Monica Bacon13, Henry C Kitchener7, Gavin Stuart3
1BSc, MD, FRCP, UCL/H Comprehensive Biomedical Research Centre, Cancer Research UK and UCL Cancer Trials Centre, 90 Tottenham Court Rd, London, W1T 4TJ, United Kingdom. E-mail: j.ledermann{at}ctc.ucl.ac.uk.
2AGO, Austria
3NCIC-CTG (Canada)
4GOG
5ANZGOG, Australia and New Zealand
6SGCTG, Scotland
7MRC/NCRI, UK;
8MITO, Italy
9National Cancer Institute
10AGO OVAR, Germany
11KGOG, Korea
12JGOG (Japan)
13GCIG;

Tóm tắt

There is now a greater understanding of the molecular pathways in ovarian cancer, and using this knowledge, a large number of new therapeutic agents can be tested. The success of these drugs will depend on selecting drugs that target known key dysfunctional molecular pathways. To make best use of these compounds, prognostic and predictive biomarkers need to be identified. Novel methods of assessment such as functional imaging need to be developed as additional biological end points to evaluate these therapies. Promising antitumor activity has been observed with some drugs, and careful consideration is needed to determine in what circumstances new agents, such as antiangiogenic compounds, could be considered as a standard therapy. These areas were discussed at the 4th Ovarian Cancer Consensus Conference.

Từ khóa


Tài liệu tham khảo

Kyzas, 2007, Eur J Cancer, 43, 2559, 10.1016/j.ejca.2007.08.030

Fayers, 1993, Int J Gynecol Cancer, 3, 285, 10.1046/j.1525-1438.1993.03050285.x

de Graeff, 2009, Br J Cancer, 101, 149, 10.1038/sj.bjc.6605112

Ahmed, 2010, J Pathol, 221, 49, 10.1002/path.2696

Brosh, 2009, Nat Rev Cancer, 9, 701, 10.1038/nrc2693

Concin, 2005, Clin Cancer Res, 11, 8372, 10.1158/1078-0432.CCR-05-0899

Zeimet, 2003, Lancet Oncol, 4, 415, 10.1016/S1470-2045(03)01139-2

Etemadmoghadam, 2009, Clin Cancer Res, 15, 1417, 10.1158/1078-0432.CCR-08-1564

Etemadmoghadam, 2010, PLoS One, 5, e15498, 10.1371/journal.pone.0015498

Farley, 2003, Cancer Res, 63, 1235

Mayr, 2006, Am J Clin Pathol, 126, 101, 10.1309/N6X5MB24BP42KP20

de Snoo, 2009, Surg Oncol, 18, 366, 10.1016/j.suronc.2009.07.005

Konstantinopoulos, 2008, Nat Clin Pract Oncol, 5, 577, 10.1038/ncponc1178

Helleman, 2010, Int J Biochem Cell Biol, 42, 25, 10.1016/j.biocel.2009.10.016

Helleman, 2010, Gynecol Oncol, 117, 170, 10.1016/j.ygyno.2010.01.010

Mackay, 2010, Int J Gynecol Cancer, 20, 945, 10.1111/IGC.0b013e3181dd0110

Winter, 2007, J Clin Oncol, 25, 3621, 10.1200/JCO.2006.10.2517

Kobel, 2008, PLoS Med, 5, e232, 10.1371/journal.pmed.0050232

Byrne, 2003, Clin Cancer Res, 9, 5721

Mesiano, 1998, Am J Pathol, 153, 1249, 10.1016/S0002-9440(10)65669-6

Duncan, 2008, Clin Cancer Res, 14, 3030, 10.1158/1078-0432.CCR-07-1888

Oehler, 2000, Anticancer Res, 20, 5109

Burger, 2007, J Clin Oncol, 25, 5165, 10.1200/JCO.2007.11.5345

Cannistra, 2007, J Clin Oncol, 25, 5180, 10.1200/JCO.2007.12.0782

Garcia, 2008, J Clin Oncol, 26, 76, 10.1200/JCO.2007.12.1939

Burger, 2010, J Clin Oncol, 28, 18S, 10.1200/jco.2010.28.18_suppl.lba1

Moroney, 2009, Future Oncol, 5, 591, 10.2217/fon.09.35

Farmer, 2005, Nature, 434, 917, 10.1038/nature03445

Audeh, 2010, Lancet, 376, 245, 10.1016/S0140-6736(10)60893-8

Fong, 2009, N Engl J Med, 361, 123, 10.1056/NEJMoa0900212

Konstantinopoulos, 2010, J Clin Oncol, 28, 3555, 10.1200/JCO.2009.27.5719

Press, 2008, BMC Cancer, 8, 17, 10.1186/1471-2407-8-17

Kalli, 2008, Gynecol Oncol, 108, 619, 10.1016/j.ygyno.2007.11.020

Armstrong, 2009, Eur J Cancer Suppl, 7, 449, 10.1016/S1359-6349(09)71522-8

Zorn, 2005, Clin Cancer Res, 11, 6422, 10.1158/1078-0432.CCR-05-0508

Markman, 2008, Gynecol Oncol, 110, 275, 10.1016/j.ygyno.2008.05.014

Avril, 2005, Radiol Clin North Am, 43, 189, 10.1016/j.rcl.2004.09.006

Bookman, 2009, J Clin Oncol, 27, 1419, 10.1200/JCO.2008.19.1684

Thông tin
Thông tin xuất bản

International Journal of Gynecological Cancer

Tập 21 Số 4

763-770

Thông tin tác giả